As a drug advances through the late stages of clinical development, formulation changes are common to meet clinical, manufacturing, and/or business needs. Since some formulation changes may alter in vivo drug absorption, it is critical to understand the impact of these changes on in vivo PK performances to support the transition between pre- and post-change formulations and ensure the drug's efficacy and safety. While clinical RBA/BE studies are time-consuming and expensive, other formulation bridging approaches that bring opportunities to expedite drug development by waiving clinical formulation bridging studies are summarized. This review discussed the current formulation bridging options based on in vitro dissolution, physiologically-based biopharmaceutics modeling (PBBM), in vitro - in vivo correlation (IVIVC), and risk-based assessment during the early and late stages of clinical development. By increasing the understanding of the opportunities and challenges associated with different formulation bridging approaches, this review helps with the selection/design of formulation bridging studies in a phase appropriate manner for formulation change during product development.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijpharm.2022.122380 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Application of Machine Learning Algorithms to Predict HIV Testing in Repeated Adult Population-Based Surveys in South Africa: Protocol for a Multiwave Cross-Sectional Analysis.
JMIR Res Protoc
January 2025
South African Medical Research Council/University of Johannesburg Pan African Centre for Epidemics Research Extramural Unit, Faculty of Health Sciences, University of Johannesburg, Johannesburg, South Africa.
Background: HIV testing is the cornerstone of HIV prevention and a pivotal step in realizing the Joint United Nations Program on HIV/AIDS (UNAIDS) goal of ending AIDS by 2030. Despite the availability of relevant survey data, there exists a research gap in using machine learning (ML) to analyze and predict HIV testing among adults in South Africa. Further investigation is needed to bridge this knowledge gap and inform evidence-based interventions to improve HIV testing.
View Article and Find Full Text PDFIs Hume's Law a valid argument against empirical bioethics?
Bioethics
January 2025
School of Public and Population Health, Institute for Bioethics and Health Humanities, The University of Texas Medical Branch, Galveston, Texas, USA.
If "no ought from is," how can bioethics be empirical? Despite the widespread recognition that we can integrate empirical and normative, Hume's Law is still often claimed to pose logical limitations to empirical bioethics. Is Hume's Law a valid argument against empirical bioethics? I argue that we have reasons to answer no. First, I outline and reject two unverified assumptions: that Hume' s Law, the fact-value distinction, and the naturalistic fallacy are roughly the same thing, and that Hume's Law is an undisputed meta-ethical principle which dictates how to formulate normative statements.
View Article and Find Full Text PDFFuture perspectives for PDE5 inhibitors bridging the gap between cardiovascular health and psychological status.
Basic Clin Androl
January 2025
Chair of Endocrinology and Medical Sexology (ENDOSEX), Dept. of Systems Medicine, University of Rome Tor Vergata, via Montpellier 1, Rome, 00133, Italy.
The serendipitous discovery that inhibiting type 5 phosphodiesterase (PDE5) using sildenafil, a potent PDE5 inhibitor (PDE5i) initially developed for cardioprotection, introduced the possibility of orally managing erectile dysfunction (ED) led to an increase in research data, which are currently considered groundbreaking for the new discipline of sexual medicine. Findings from a number of laboratories and clinics around the world unanimously demonstrated the following: (i) the major cause of ED is directly or indirectly related to cardiovascular disease (CVD); (ii) ED and CVDs share the same risk factors, which are related mainly to lifestyle choices; (iii) the first therapeutic approach to both ED and CVDs is to transform harmful lifestyles into virtuous lifestyles; and (iv) PDE5is in general, particularly sildenafil, are very safe, if not protective, for use in CVD patients. However, the use of PDE5is has faced several challenges.
View Article and Find Full Text PDFVat photopolymerization (VPP) is an additive manufacturing method that requires the design of photocurable resins to act as feedstock and binder for the printing of parts, both monolithic and composite. The design of a suitable photoresin is costly and time-consuming. The development of one formulation requires the consumption of kilograms of costly materials, weeks of printing and performance testing, as well as the need to have developers with the expertise and knowledge of the materials used, making the development process cost thousands.
View Article and Find Full Text PDFFrom Polydeoxyribonucleotides (PDRNs) to Polynucleotides (PNs): Bridging the Gap Between Scientific Definitions, Molecular Insights, and Clinical Applications of Multifunctional Biomolecules.
Biomolecules
January 2025
Regenerative Therapy Unit, Lausanne University Hospital, University of Lausanne, CH-1066 Epalinges, Switzerland.
Polydeoxyribonucleotides (PDRNs) and polynucleotides (PNs) are similar DNA-derived biopolymers that have garnered significant scientific attention since the 1990s for their potential applications in wound healing and skin rejuvenation. These biopolymers exhibit a broad molecular weight (MW) range, typically spanning from 50 to 1500 kDa. However, recent studies have expanded this range to encompass fragments as small as 1 kDa and as large as 10,000 kDa.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!